Mark G. Kris

Mark Kris is one of the founding fathers of modern thoracic oncology who championed early adoption of molecular profiling in lung cancer care. He led MSK's Lung Cancer Mutation Consortium studies that systematically identified actionable driver mutations including ALK rearrangements in a large real-world cohort. His advocacy for routine molecular testing in NSCLC helped define the standard of care for all patients with advanced disease. He has trained generations of thoracic oncologists and remains active in guideline development.